10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Mercaptopurine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Mercaptopurine

Mercaptopurine

Class : C!

Show all info

Print

Contact us

  1. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022;128(9):1863-1870.

  2. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.

  3. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.

  4. Puri-nethol (mercaptopurine). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2023-06-30, cited 2023-08-07]

  5. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705-13.

  6. Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest. 1993;53(7):747-9.

  7. Serpe L, Calvo PL, Muntoni E, D'Antico S, Giaccone M, Avagnina A et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics. 2009;10(11):1753-65.

  8. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7(12):1816-23.

  9. Escherich G, Richards S, Stork LC, Vora AJ, Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia. 2011;25(6):953-9.

  10. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37(1):10-9.

  11. Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol. 1995;13(2):345-51.

  12. Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. Br J Cancer. 1984;49(6):703-7.

  13. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022;128(9):1863-1870.
  2. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  3. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
  4. Puri-nethol (mercaptopurine). Summary of Product Characteristics. Swedish Medical Products Agency (MPA) [updated 2023-06-30, cited 2023-08-07]
  5. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118(4):705-13.
  6. Klemetsdal B, Wist E, Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest. 1993;53(7):747-9.
  7. Serpe L, Calvo PL, Muntoni E, D'Antico S, Giaccone M, Avagnina A et al. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics. 2009;10(11):1753-65.
  8. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7(12):1816-23.
  9. Escherich G, Richards S, Stork LC, Vora AJ, Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia. 2011;25(6):953-9.
  10. Ishii E, Eguchi H, Matsuzaki A, Koga H, Yanai F, Kuroda H et al. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. Med Pediatr Oncol. 2001;37(1):10-9.
  11. Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol. 1995;13(2):345-51.
  12. Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization. Br J Cancer. 1984;49(6):703-7.
  13. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]